PA-PCI-PHARMA-SERVICES
PCI Pharma Services (PCI), a leading global contract development and manufacturing organization (CDMO), has successfully completed the International Coalition of Medicines Regulatory Authorities (ICMRA) inspection of its Bedford, New Hampshire campus. In doing so, PCI becomes the first drug product CDMO to navigate the multi-agency inspection process, a facet of the ICMRA’s new Collaborative Hybrid Inspection Pilot (CHIP) program, which is focused on the mutual assessment of facilities that manufacture therapies under the organization’s purview.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240821206732/en/
PCI becomes first drug product CDMO to navigate ICMRA multi-agency inspection process. (Photo: Business Wire)
The new ICMRA program is designed to abbreviate the time necessary to receive regulatory approvals from multiple countries. Regulatory agencies from several countries can convene for one inspection as a team, allowing CDMOs such as PCI to attain approval from each of the participating ICMRA countries simultaneously rather than undergo separate, phased inspections. For this pilot inspection, two agencies conducted the inspection – one onsite and the other virtually – while an additional five regulatory bodies observed virtually.
“We’re honored to have been selected as the first CDMO to participate in the ICMRA’s pilot program, allowing for agencies across the globe to conduct their regulatory approval process simultaneously,” said Tom McGrath, VP, Global Quality for Manufacturing & Development at PCI Pharma Services. “The program’s collaborative, comprehensive process increases the speed at which CDMOs or sponsoring pharma companies can begin manufacturing, packaging and ultimately commercializing life-changing therapies.”
PCI’s Bedford campus specializes in sterile fill-finish and lyophilization, two manufacturing processes commonly used with injectable and biologic therapies. PCI recently invested over $100 million in infrastructure enhancements at the site, building upon legacy disciplines toward its current destination: a multi-product, multi-capabilities campus servicing prominent pharma companies, across the drug product lifecycle from development to commercialization. Since PCI’s Bedford campus manufactures a broad array of drugs for both domestic and international markets, the site was an ideal candidate for the multi-agency inspection pilot program.
“At PCI, we are dedicated to bringing lifechanging therapies to patients as expediently as possible, and this welcome new program will further enhance our ability to do exactly that,” said Salim Haffar, CEO of PCI Pharma Services. “The ability to simultaneously gain approval from multiple, geographically diverse regulatory agencies is a game-changing, fast-tracking boost for the pharma industry, providing shorter paths to full-fledged sterile drug product production and commercialization, to the ultimate benefit of pharma companies and the patients they serve.”
About PCI Pharma Services
PCI is a world leading CDMO, providing clients with integrated end-to-end drug development, manufacturing and packaging capabilities that increase their products’ speed to market and opportunities for commercial success. PCI brings the proven experience that comes with more than 90 successful product launches each year and over five decades in the healthcare services business. The company currently has 30 sites across seven countries (Australia, Canada, U.S., Ireland, Wales, Germany and Spain), and over 7,000 employees working to bring life-changing therapies to patients.
Leading technology and continued investment enable PCI Pharma Services to address global drug development needs throughout the entire product life cycle – from manufacturing capabilities through the clinical trial supply chain and commercialization. Its clients utilize PCI as an extension of their business, and a collaborative partner with the shared goal of improving patients’ lives. For more information, visit pci.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240821206732/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phenom Named Strategic Leader in 2024 Fosway 9-Grid™ for Talent & People Success10.10.2024 11:30:00 CEST | Press release
Positioning Recognises Phenom’s Impact on Helping Europe’s Largest Companies Solve HR’s Biggest Talent Management Challenges Phenom has been named a Strategic Leader in the 2024 Fosway 9-Grid™ for Talent and People Success, a testament to the value delivered by the AI-powered Phenom Intelligent Talent Experience platform, which makes new employees productive faster, enhances development and increases retention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241010930504/en/ Phenom has been named a Strategic Leader in the 2024 Fosway 9-Grid™ for Talent and People Success, a testament to the value delivered by the AI-powered Phenom Intelligent Talent Experience platform, which makes new employees productive faster, enhances development and increases retention. (Graphic: Business Wire) Fosway Group identifies Strategic Leaders as companies that provide a rich suite of capability across a broad scope of features and have the sop
Thredd Reports Another Successful Quarter With Fintech Transaction Volumes up and New Issuer Signings10.10.2024 11:08:00 CEST | Press release
20% YOY organic transaction volume growth and new client signings in APAC and the U.S. 48% increase YOY in Buy Now Pay Later (BNPL) solutions across the UK, Europe, and APAC regions B2B virtual card payments up significantly with APAC clients leading the charge Thredd, a leading next-generation payments processor, today announced positive third-quarter results with 2024 on track to outperform all prior years, powered by transactions up 20%, key global client wins, programme expansions and growth in distinct payment segments and markets. According to the company, Thredd signed key new clients in the third quarter including digital banks and saw existing B2B programme expansion to the US. The company also announced the launch of virtual card programmes and a major card programme migration in APAC. The company said these wins and programme launches follow other partnership extensions earlier in the summer with segment leaders in Buy Now Pay Later (BNPL), B2B payments, disbursements, and s
Allianz Is the World’s #1 Insurance Brand, Ranking Among the Top 30 Global Brands for the First Time10.10.2024 11:03:00 CEST | Press release
Interbrand 2024 Best Global Brands ranking: Allianz jumps to 29th position and further maximises brand value to 23,5 billion USD.Strong employee value proposition: Allianz also climbed to 7th place in the Fortune 100 Best Companies to Work For® in Europe 2024 certification.The 2024 Olympic and Paralympic Games in Paris have been the biggest marketing asset to date for Allianz, uniting athletes from over 200 nations and billions of fans in peaceful competitions.Disaster relief efforts for flood events and sustainability commitments contribute to building trust in the Allianz brand. Allianz's steady rise to the top of the world's most powerful brands continued in 2024, driven by a strong employee value proposition, a commitment to building trust through sustainability and societal leadership as well as top-tier partnerships in sport. For the first time, Allianz has been named one of the 30 most valuable brands in the world, moving up two places to the 29th position in this year’s Best Gl
MiLaboratories Secures Series A, Raising Total Funding to $10 Million to Revolutionize the World of Genomic Research10.10.2024 09:01:00 CEST | Press release
The San Francisco-based company with an R&D facility in Bilbao has also unveiled its Platforma.bio Software Development Kit, transforming how biologists analyze genomic data to drive drug discovery and advance adjacent fields in medicine. This latest financing bolsters the company's efforts to transform computational biology on a global scale and empower researchers with innovative tools to accelerate discoveries and advancements in the field Led by Kfund with participation from Speedinvest, Acrobator Ventures, Ten13, Somersault Ventures, EGB Capital, and Courtyard Ventures Series A capital to be utilized for attracting top-tier talent and expanding into new markets, with a strategic emphasis on the United States MiLaboratories, a leader in computational biology innovation, is thrilled to announce the successful close of its Series A funding round, led by Madrid-based Kfund, with additional backing from Speedinvest and other prominent international investors. This funding milestone com
Delinea Recognized as a Leader in the KuppingerCole Leadership Compass™ for Privileged Access Management (PAM) 202410.10.2024 09:00:00 CEST | Press release
Delinea’s Continued Innovation and Comprehensive Approach to Identity Security Highlighted in Leading Analyst Report Delinea, a pioneering provider of solutions for securing identities through centralized authorization, today announced its recognition as a Leader in the KuppingerCole Leadership Compass for Privileged Access Management (PAM), 2024. This marks another significant milestone for Delinea as it continues to lead the industry in providing secure and scalable PAM solutions that empower organizations to safeguard their most critical identities and assets. “We are honored to be recognized as a Leader in the 2024 KuppingerCole Leadership Compass for PAM,” said Art Gilliland, CEO of Delinea. “This achievement reflects our commitment to developing innovative solutions for the growing complexity of identity security. With our broad product portfolio and cloud-first approach, Delinea has established itself as a market leader known for ease of use. As human and machine identities incr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom